1 min read
Emmaus Life Sciences Reports $0.07 Q3 Loss as Revenue Falls 43.8%
Third-quarter revenue was $1.9 million. Cash and cash equivalents totaled $1.0 million at Sept. 30, down from $2.1 million at Dec. 31, 2025.

Emmaus Life Sciences posted a third-quarter GAAP loss of $0.07 per share as revenue fell 43.8% year over year to $1.9 million.
The company had $1.0 million in cash and cash equivalents at Sept. 30, compared with $2.1 million at Dec. 31, 2025.